Several types of tumors (basal cell carcinomas, gliomas, medullablastomas, and prostate cancer) express abnormally high levels of GLI proteins or increased SHH pathway activation, which may be targets for therapy [42]. Here, GLI1 is linked to prostate carcinoma.